Known primarily as the parent company of CorCell, which facilitates umbilical cord blood stem cell preservation for expectants and their children, Cord Blood America has quickly developed a stellar reputation within their industry. Today Cord Blood took a major step towards further prominence with the announcement they have entered into a major agreement with BlueCross BlueShield (BCBS) of Tennessee.
Cord Blood will now offer storage of umbilical cord blood at a discount rate as consistent with its other BCBS licensee contracts. While Blue Cross has a total enrollment of 3 million, more than half of these members are located in Tennessee.
Leading the way at Cord Blood is Matthew Schissler whom serves as the company’s CEO. Commenting on the agreement with BCBS, Schissler was quoted as saying, “Tennessee is in the forefront of educating pregnant women about cord blood banking options because of legislation passed in the state. We are pleased that CorCell, our United States brand, can partner with BlueCross and offer these important, potentially life-saving services, to their members. We will also be offering courses to nurses and other healthcare professionals on the value of stem cell storage.”
As of right now Cord Blood stem cells are utilized to treat more than 70 diseases. Many of these diseases have no current cure. By providing relief to these patients and their families, Cord Blood has quickly become a friend of investors and the healthcare sector as a whole.
To learn more about this up-and-coming company, visit the corporate website at www.cordblood-america.com